← Back to Clinical Trials
Recruiting NCT06883045

NCT06883045 A Novel mHealth Intervention to Improve Outcomes of Children With Medical Complexity

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06883045
Status Recruiting
Phase
Sponsor University of Utah
Condition Children With Medical Complexity
Study Type INTERVENTIONAL
Enrollment 360 participants
Start Date 2026-01-06
Primary Completion 2029-03-31

Eligibility & Interventions

Sex All sexes
Min Age 1 Year
Max Age 18 Years
Study Type INTERVENTIONAL
Interventions
MyChildCMC app (an app designed to facilitate home monitoring of CMC's health status)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 360 participants in total. It began in 2026-01-06 with a primary completion date of 2029-03-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Children with medical complexity (CMC) are the most vulnerable of children with chronic diseases, who have complex, multisystem chronic diseases affecting ≥3 organ systems, severe functional limitations and technology dependencies. CMC have high health care needs, and account for 40% of hospitalized children and 35% of all pediatric health care costs. Due to high medical fragility, CMC have frequent acute deteriorations superimposed on their chronic conditions, leading to recurrent emergency department (ED)/hospital admissions and affecting quality of life (QOL). To reduce ED/hospital admissions for CMC, remote monitoring is suggested, with use of mHealth apps to regularly assess their health status remotely and identify early signs of acute deterioration, allowing for early interventions to prevent ED/hospital admissions. Yet no app to support remote monitoring of CMC exists. Variable, multisystem conditions among CMC make it difficult to develop an app. Also, many CMC are at high-risk for health care inequities, with minorities having higher unmet needs, but the impacts of health care inequities and social determinants of health (SDOH) on ED/hospital admissions in CMC are rarely studied. Fortunately, ED/hospital admissions for CMC are often preceded by a limited set of shared (crosscutting) acute symptoms. These crosscutting symptoms rarely occur suddenly. Studies suggest that they usually start as subtle signs, often unnoticed by parents until they escalate to prompt an ED/hospital visit. Thus, crosscutting symptoms offer an opportunity for a novel and practical approach for developing a remote monitoring app for CMC, despite their multiple, variable underlying conditions. In a focus group, parents identified the crosscutting symptoms that most often preceded their children's hospital admissions, and conveyed their needs, preferences and key functionalities that led to MyChildCMC, the first app designed to monitor and identify early signs of crosscutting symptoms in CMC. In a pilot trial of 50 subjects, we confirmed feasibility of MyChildCMC use by parents, ability to detect early signs 2-14 days prior to ED/hospital admissions, and use leading significantly to fewer hospital days than controls. The current study will assess the efficacy and sustainability of MyChildCMC in a fully-powered 6-month, 2-arm (MyChildCMC vs usual care) trial of CMC (age 1-18 years) and their parents. Parents assigned to MyChildCMC will use the app daily for 6 months, both arms will receive financial incentive for participation, then we will stop the incentive and follow subjects for 6 more months to assess sustainability at 12 months. We will also assess if MyChildCMC use will help reduce or eliminate inequities in ED/hospital admissions. Specific Aims are: 1) Determine MyChildCMC's efficacy on 1.a. Child (ED/hospital use, hospital days and QOL) and 1.b. Parent (satisfaction, self-efficacy and stress) outcomes; 2) Compare ED/hospital use among racial/ethnic and SDOH subgroups to assess potential effect of MyChildCMC on inequities.

Eligibility Criteria

Inclusion Criteria: * CMC, ages 1-18 years and their parents (or primary caregivers) * CMC (inpatients or outpatients) who receive care at participating sites (comprehensive care clinics for CMC) * Own (or provided) a smartphone or tablet with internet access * Speak English or Spanish. * CMCs are identified using an operational definition, as having: 1) multisystem chronic diseases involving ≥3 organ systems, 2) ≥3 HCPs involved in their care, 3) high fragility or frequent (≥2) or 1 prolonged (\>10 days) hospitalization in the prior year, and/or 4) medical technology dependence. Exclusion Criteria: * Critically ill CMC and infants. * CMC exhibit similar developmental and functional abilities and typically function below expected for a 7-year-old child, allowing inclusion of a wide age range in studies. * Infants were excluded as many CMC \<1 year have prematurity-related conditions that may resolve by age 2. * CMC \>18 years of age were not included as some may transition to adult health care. * Note: No one will be excluded due to lack of smartphone/internet access. We estimated \<10% of families may not have a smartphone/internet, and will provide them low-cost tablets and cellular internet access.

Contact & Investigator

Central Contact

Flory L Nkoy, MD, MS, MPH

✉ flory.nkoy@hsc.utah.edu

📞 8012134161

Principal Investigator

Flory Nkoy, MD, MS, MPH

PRINCIPAL INVESTIGATOR

University of Utah

Frequently Asked Questions

Who can join the NCT06883045 clinical trial?

This trial is open to participants of all sexes, aged 1 Year or older, up to 18 Years, studying Children With Medical Complexity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06883045 currently recruiting?

Yes, NCT06883045 is actively recruiting participants. Contact the research team at flory.nkoy@hsc.utah.edu for enrollment information.

Where is the NCT06883045 trial being conducted?

This trial is being conducted at Chicago, United States, Salt Lake City, United States.

Who is sponsoring the NCT06883045 clinical trial?

NCT06883045 is sponsored by University of Utah. The principal investigator is Flory Nkoy, MD, MS, MPH at University of Utah. The trial plans to enroll 360 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology